It is the only CD19-targeting T cell engager advancing globally with both EMA and U.S. FDA regulatory clearance. Dr. Jeffrey Jones, CMO of Cullinan, emphasized the drug's potential for disease ...

We welcome the swift approval by the EMA on this additional subcutaneous administration option. “HAE patients 12 years and older now have an additional individualised treatment option available ...

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of a new Opdivo (nivolumab) formulation ...

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variation application to the European Medicines Agency ...